MRK · News · 20260914N

Competition and Market Share

Merck & Co., Inc. · 2026-09-14 · Importance 17 · Surprise 24

Merck and Moderna are described as leading the personalized cancer vaccine race following a significant melanoma result and a Phase 3 advance for Moderna’s AI-designed cancer vaccine. The competitive field includes Roche/BioNTech, BioNTech, OSE Immunotherapeutics, Elicio Therapeutics and Agenus. Approaches span personalized mRNA vaccines, off-the-shelf T-cell epitope therapies and dual-antibody treatments across multiple cancer types, increasing competitive pressure on Merck’s oncology vaccine collaboration.